All In Biotech

Drug Trial Radar · NCT06613100

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, and Feasibility of Neoadjuvant Xaluritamig Therapy Prior to Radical Prostatectomy in Subjects With Newly Diagnosed Localized Intermediate or High-Risk Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Nov 25, 2024

Primary completion

Feb 17, 2027

Study completion Mar 4, 2030

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Sep 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered as monotherapy or in combination with an oral Gonadotropin-releasing Hormone (GnRH) antagonist in the neoadjuvant setting followed by radical prostatectomy, and to evaluate the feasibility and safety of a radical prostatectomy following xaluritamig administered as monotherapy or in combination with an oral GnRH antagonist in the neoadjuvant setting.

Conditions

  • Prostate Cancer

Interventions

  • XaluritamigDrug

    Intravenous (IV) infusion

  • GnRH AntagonistDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants who Experienced Treatment-emergent Adverse EventsTime frame: Up to 45 months
  2. Number of Participants who Experienced Treatment-related Adverse EventsTime frame: Up to 28 months
  3. Number of Participants who Received Radical Prostatectomy After Completing Xaluritamig TreatmentTime frame: Up to 25 months
  4. Number of Participants who Experienced Complications of Radical Prostatectomy According to Clavien-Dindo ClassificationTime frame: Up to 28 months

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California San Francisco

    San Francisco, California · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • The Ohio State University

    Columbus, Ohio · Recruiting

  • Thomas Jefferson University

    Philadelphia, Pennsylvania · Recruiting

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Universitaetsklinikum Essen

    Essen, Germany · Recruiting

  • Universitaetsklinikum Hamburg Eppendorf

    Hamburg, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.